When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved for psoriasis focused on patient populations with infestation of these difficult-to-treat body regions.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Current evidence, risk classes and new counseling options
Hormonal contraception and cardiovascular risk
- Acute otitis media: self-limiting course vs. "red flags"
In which cases are antibiotics necessary?
- Prurigo nodularis: evidence-based treatment
Targeted therapy options on the rise
- MACE risk, heart failure incidence and all-cause mortality
Metabolic syndrome as a cardiovascular risk factor
- Glaucoma in old age: slowing down progression
IOP lowering is currently the only evidence-based treatment
- Vector-borne infections with skin manifestations
Arboviruses and leishmaniasis in Europe
- Multimorbidity and functional capacity in old age
Clarify individual health status and reduce risks
- Tick season: danger from early summer meningoencephalitis